Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin immunoconjugate, in rats and dogs

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 6, 2000, Pages 671-678

  Damle, Bharat ^a   Tay, Lee ^a   Comereski, Charles ^b   Warner, William ^b   Kaul, Sanjeev ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BMS191352; IMMUNOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; IMMUNOGENICITY; NONHUMAN; RAT;

EID: 0034131512     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001774345     Document Type: Article

References (16)

1. Bocci, V. (1987) Metabolism of protein anticancer agents. Pharmacol. Ther. 34: 1-49
2. Chiou, W. L. (1979) Equations for estimation of first-pass effect and apparent distribution volume of a drug with incomplete oral absorption and partial renal excretion. J. Pharm. Sci. 68: 260
3. Damle, B., Hollenbaugh, D., Timoszyk, J., Tay, L., Kaul, S. (1998) Development of an immunoassay for BMS-191352, a single-chain immunotoxin, and its application to toxico-kinetic studies. J. Immunoassay 19: 145-165
4. Davies, B., Morris, T. (1993) Physiological parameters in laboratory animals and humans. Pharm. Res. 10: 1093-1095
5. Ferraiolo, B. L., Mohler, M. A. (1992) Goals and analytical methodologies for protein disposition studies. In: Ferraiolo, B. L., Mohley, M. A., Gloff, C. A. (eds) Protein Metabolism and Pharmacokinetics. Plenum Press, New York, pp 1-33
6. Friedman, P. N., McAndrew, S. J., Gawlak, S. L., Chace, D., Trail, P. A., Brown, J. P., Siegall, C. B. (1993) BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res. 53: 334-339
7. Gibaldi, M., Perrier, D. (1982) Non-compartmental analysis based on statistical moment theory. In: Gibaldi, M., Perrier, D. (eds) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 409-418
8. Liddell, J. E., Cryer, A. (1991) Characterization, purification, and labeling. In: Liddell, J. E., Cryer, A. (eds) A Practical Guide to Monoclonal Antibodies. John Wiley & Sons Ltd, West Sussex, UK, pp 105-138
9. Morgan, A. C., Manger, R., Pearson, J. W., Longo, D., Abrams, P., Sivam, G., Bjorn, M. (1991) Immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkey, and man. Cancer Detect. Prev. 15: 137-143
10. Ogata, M., Pastan, I., Fitzgerald, D. (1991) Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect. Immunol. 59: 407-414
11. Pond, S. M., Tozer, T. N. (1984) First-pass elimination: Basic concepts and clinical consequences. Clin. Pharmacokinet. 9: 1-25
12. Roitt, I. M. (1997) The primary interaction with antigen. In: Roitt, I. M. (ed.) Essential Immunology, 9th edn. Blackwell Sciences Ltd, London, pp 80-101
13. SAS/STAT Users Guide (1989) Version 6. 4th edn. SAS Institute Inc., Cary, NC
14. Siegall, C. B., Chace, D., Mixan, B., Garrigues, U., Wan, H., Paul, L., Wolff, E., Hellström, I., Hellström, K. E. (1994) In vitro and in vivo characterization of BR96 sFv-PE40: a single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J. Immunol. 152: 2377-2384
15. Sjogren, H. O., Isaksson, M., Willner, D., Hellstrom, I., Hellstrom, K. E., Trail, P. A. (1997) Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 57: 4530-4536
16. Wawrzynczak, E. J. (1991) Systemic immunotoxin therapy in cancer: advances and prospects. Br. J. Cancer 64: 624-630